All News StemRIM

Equities

4599

JP3399690001

Delayed Japan Exchange Other stock markets 09:06:42 2024-06-02 pm EDT			5-day change	1st Jan Change
461 ^JPY	-0.43%		+1.77%	-20.24%

May. 09	StemRIM to Seek Shareholders' Approval on Capital Stock Reduction	MT
Mar. 13	StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

StemRIM to Seek Shareholders' Approval on Capital Stock Reduction	May. 09	MT
StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy	Mar. 13	CI
StemRIM Inc. Announces Patent Registration for the Use of the HMGB1 Fragment Peptide, as an Additional Therapeutic Indication of Cartilage Disorders	Jan. 31	CI
StemRIM Allocates 300 Stock Options to R&D Partner	Dec. 28	MT
StemRIM to Issue Stock Acquisition Rights	Dec. 13	MT
StemRIM Issues Over 300 Million Yen of Shares as Restricted Stock Compensation	Dec. 06	MT
StemRIM Enters into Contract for Implementation of Phase 2 Investigator-Initiated Clinical Trial Targeting Ischemic Cardiomyopathy Using Redasemtide, in Collaboration with Osaka University Hospital and Shionogi & Co	Dec. 04	CI
StemRIM Issues 433,000 Shares as Restricted Stock Compensation	Nov. 17	MT
StemRIM, Shiseido, Osaka University Extend Skin Aging Research Collaboration	Nov. 17	MT
StemRIM Discloses Issuance Details of Stock Options to Directors	23-09-20	MT
Stemrim Inc. Announces Patent Registration (Us) for the Use of the Hmgb1 Fragment Peptide, Redasemtide	23-09-06	CI
StemRIM Announces Patent Registration for the Use of Redasemtide as an Additional Treatment for Cardiomyopathy and Old Myocardial Infarction	23-09-04	CI
StemRIM Inc. Announces the First Administration of Global Late Phase 2 Clinical Trials for Redasemtide Targeting Acute Ischemic Stroke	23-07-31	CI
StemRIM Inc. Announces Commencement of Global Late Phase 2 Clinical Trial for Redasemtide in Patients with Acute Ischemic Stroke in the Europe and China	23-07-25	CI
StemRIM Inc. Announces Patent Registration for the Use of the Hmgb1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy and Old Myocardial Infarction	23-07-18	CI
StemRIM Provides Earnings Guidance for the Year Ending July 31, 2023	23-06-18	CI
Shionogi & Co., Ltd. - Orphan Drug Designation for Redasemtide for Dystrophic Epidermolysis Bullosa	23-05-24	AQ
StemRIM Inc. Announces Publication of Scientific Articles for Stem Cell Gene Therapy	23-05-16	CI
StemRIM Announces Milestone Achievement in Development of Therapeutic Drug (Redasemtide) Targeting Acute Ischemic Stroke	23-04-28	CI
StemRIM Bags 450 Million Yen Milestone Payment From Shionogi; Details FY23 Earnings Outlook, Liver Disease Trial Results	23-04-12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News StemRIM

Equities

4599

JP3399690001

All News

Filters